Trials / Completed
CompletedNCT02229461
Naproxen Sodium/ASA Platelet Study
A Randomized, Open Label, Parallel Group Study to Investigate the Effects on Serum Thromboxane by the Addition of Naproxen Sodium to Aspirin Therapy Versus Aspirin Therapy Alone
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 117 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
To determine if administration of naproxen sodium 220 mg maintains the platelet inhibitory effect of a low dose Immediate Release Aspirin (IR ASA) regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Naproxen Sodium (Aleve, BAY117031) | Naproxen sodium 220 mg qd or bid |
| DRUG | Acetylsalicylic Acid (Aspirin, BAYE4465) | ASA 81 mg qd |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2014-09-01
- Last updated
- 2016-07-15
- Results posted
- 2016-06-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02229461. Inclusion in this directory is not an endorsement.